Gabexate is a serine protease inhibitor which is used therapeutically (as gabexate mesilate) in the treatment of pancreatitis, disseminated intravascular coagulation,[1] and as a regional anticoagulant for haemodialysis.[2]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H23N3O4 |
Molar mass | 321.377 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
References
edit- ^ Yuksel M, Okajima K, Uchiba M, Okabe H (2003). "Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes". J. Pharmacol. Exp. Ther. 305 (1): 298–305. doi:10.1124/jpet.102.041988. PMID 12649382. S2CID 23518949.
- ^ Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V (1996). "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group". N. Engl. J. Med. 335 (13): 919–23. doi:10.1056/NEJM199609263351302. PMID 8786777.